ReviewInternational journal of nanomedicine2026
Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticles Navigating the Blood-Brain Barrier for Neurodegenerative Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease is a progressive neurological disorder marked by motor, cognitive, and psychiatric symptoms. Currently, there are no definitive diagnostic tools or effective treatments to halt or reverse the disease. In recent years, surface-engineered nanosystems have emerged as innovative therapeutic platforms, offering significant promise in overcoming the limitations of traditional approaches. These nano systems, including liposomes, dendrimers, polymeric nanoparticles, and solid lipid nanoparticles, offer significant potential by targeting and modulating intricate biochemical pathways involved in the progression of Huntington's disease. Their defining advantage lies in the ability to selectively deliver therapeutic agents to specific regions of the brain with high precision. Through the use of various nanoscale carriers, these particles can successfully traverse the protective barrier between the blood and brain tissue, enabling the direct delivery of treatment agents to the regions affected by Huntington's disease. This targeted approach not only enhances the therapeutic efficacy but also minimizes unwanted systemic side effects. This review highlights recent advancements in nanosystem development, addressing previous challenges and setbacks in the field, particularly in overcoming the blood-brain barrier and improving treatment delivery. The review further explores the evolving mechanisms of nanosystem delivery and their functional impact in experimental models of Huntington's disease. While the primary focus remains on therapeutic applications, we also briefly discuss recent developments in nanoparticle-based diagnostics. Although several challenges, particularly regarding comprehensive safety assessments and the current absence of nanoparticles approved by the United States Food and Drug Administration for Huntington's disease, this review underscores the transformative potential of nanosystems for future therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.